Researcher

Alimuddin Zumla

Center for Clinical Microbiology, Institute of Infection, Immunity and Transplantation, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK; NIHR Biomedical Research Centre, Univers

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

JOURNAL ARTICLE

Advances in tuberculosis diagnostics and biomarkers, 2020-26: scientific evidence, recommendations, gaps, and developmental priorities.

The Lancet. Microbe

This is a WHO policy synthesis and scientific evidence review consolidating diagnostic and biomarker advances from 2020–25, informing updated recommendations for TB detection and drug resistance across populations and specimen types.

Expert GuidanceGerhard Walzl Jeremiah Chakaya Suvanand Sahu

JOURNAL ARTICLE

Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines.

The Lancet. Microbe

A comprehensive narrative review synthesizing pivotal trial evidence and WHO guideline updates on tuberculosis treatment innovation since 2020, without reporting new primary efficacy data.

Expert GuidanceBen J Marais Simon Tiberi Delia Goletti

Reported

Estimated tuberculosis incidence…10.7 million

Estimated tuberculosis deaths glo…1.23 million

JOURNAL ARTICLE

Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access.

The Lancet. Microbe

A narrative review synthesizing current evidence on TB vaccine pipelines and preventive therapies, providing clinical and policy guidance rather than reporting primary efficacy data.

Expert GuidanceBen J Marais Philip Onyebujoh Delia Goletti

Reported

TB vaccine candidates in clinical…6

Total TB vaccine candidates in ac…18

Estimated TB cases in 202410·7 million